Former FDA counsel: Off-label marketing ban in jeopardy

11/3/2011 | Wall Street Journal, The

Drugmakers have filed a friends-of-the-court brief asserting that marketing drugs for unapproved uses is protected free speech. FDA rules prohibiting off-label marketing are meant to protect patients, says Thomas W. Abrams, director of the FDA's Division of Drug Marketing, Advertising and Communications. Former FDA chief counsel Richard Cooper said a Supreme Court ruling in June on pharmacy records could put the FDA's ban on off-label marketing "in some jeopardy."

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Director, Payer Marketing
Avalere Health
Washington, DC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX